Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy

NCT ID: NCT00895011

Last Updated: 2012-10-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 298 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-04-30
• Study Completion Date: 2011-04-30

Brief Summary

The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing radical prostatectomy.

Conditions

Erectile Dysfunction

Keywords

Erectile Dysfunction; E.D.

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

One dose 30 minutes prior to initiation of sexual activity

Avanafil 100 mg

Group Type: EXPERIMENTAL

Avanafil

Intervention Type: DRUG

One dose 30 minutes prior to initiation of sexual activity

Avanafil 200 mg

Group Type: EXPERIMENTAL

Avanafil

Intervention Type: DRUG

One dose 30 minutes prior to initiation of sexual activity

Interventions

Placebo

One dose 30 minutes prior to initiation of sexual activity

Intervention Type: DRUG

Avanafil

One dose 30 minutes prior to initiation of sexual activity

Intervention Type: DRUG

Avanafil

One dose 30 minutes prior to initiation of sexual activity

Intervention Type: DRUG

Other Intervention Names

TA-1790; Stendra; TA-1790; Stendra

Eligibility Criteria

Inclusion Criteria

• Adult males ≥ 18 years and ≤ 70 years;
• Have a history of erectile dysfunction of at least 6 months duration following bilateral nerve-sparing retropubic radical prostatectomy;
• Have a PSA level consistent with the absence of prostate cancer;
• Have a history of sexual potency prior to radical prostatectomy without requiring medical therapy;
• Be in a monogamous, heterosexual relationship with their current partner for at least 3 months;
• Provide written informed consent;
• Agree to make at least 4 attempts at intercourse per month;
• Agree not to use any other treatments for erectile dysfunction;
• Be willing and able to comply with all study requirements (including scheduled study visits, treatment plans, laboratory tests and other study procedures).

Exclusion Criteria

• Allergy or hypersensitivity to PDE5 inhibitors or any of the components of these drug products;
• History of dose-limiting AEs during prior treatment with a PDE5 inhibitor or discontinued use of a PDE5 inhibitor due to lack of efficacy at the highest tolerated dose;
• Concomitant use of one or more of the following medications:

• Any nitrate, trazodone, itraconazole, ketoconazole, erythromycin, or cimetidine;
• Other prescription or OTC drugs that are known to interfere with metabolism by the CYP 3A4 enzyme;
• If receiving hormone replacement therapy (including thyroid supplementation), dose that has not been stable for at least 3 months;
• If treated with an alpha blocker, dose that has not been stable for at least 14 days;
• Erectile dysfunction as a consequence of advanced neurologic disease, spinal cord injury, or diabetes;
• History of severe erectile dysfunction requiring medical therapy prior to bilateral nerve-sparing radical prostatectomy;
• History of previous pelvic surgery, brachytherapy, or cryotherapy of the prostate;
• Sexual partner who is under 18 years of age, pregnant, intends to become pregnant during the course of the study, is breastfeeding, has dyspareunia or other gynecologic conditions or other major medical conditions that would interfere with sexual activity or would have difficulty complying with study requirements;
• Uncontrolled hypertension;
• Hypotension;
• Orthostatic hypotension;
• Myocardial infarction, stroke, life-threatening arrhythmia or coronary revascularization within the past 6 months;
• Unstable angina, angina with sexual intercourse, or congestive heart failure > NYHA Class II;
• History or ECG evidence of any high-risk arrhythmia or clinically significant ECG;
• Hypertrophic, obstructive, or other clinically significant cardiomyopathy, moderate or severe cardiac valvular disease;
• Type 1 or type 2 diabetes, history of use of any antidiabetic medication;
• Clinically evident penile lesions, abrasions, anatomical deformities such as penile fibrosis, Peyronie's disease, penile implants, urinary tract or bladder infection, or sexually transmissible disease that the investigator deems to be clinically significant;
• Condition(s) predisposing to priapism, such as sickle cell disease , multiple myeloma, or leukemia;
• Any malignancy other than carcinoma of the prostate (except basal cell carcinoma or squamous cell carcinoma of the skin);
• Prior use of, or likely to require radiotherapy, chemotherapy, androgen deprivation therapy, cryotherapy, non-nerve-sparing surgery, and/or bladder or penile surgery during the study;
• Evidence of significant hepatic impairment;
• On dialysis, or history of renal transplantation;
• Untreated hypogonadism or low serum total testosterone;
• Abnormal laboratory value(s) judged to be clinically significant by the investigator;
• Positive STD screen (syphilis, gonorrhea, or chlamydia);
• Positive for HIV, HCV Ab, or HBsAg at screening;
• History or current drug, alcohol, or substance abuse;
• Positive urine drug screen;
• Positive breath alcohol test;
• Retinitis pigmentosa or nonarteritic anterior ischemic optic neuropathy;
• Use of any treatment or device for treatment of erectile dysfunction;
• Use of any other investigational medication or device for any indication within 30 days prior to enrollment or at any time during this study;
• Previous participation in any other investigational study of avanafil;
• Any history of bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity or antidepressant use that has not been stable for at least 3 months;
• Involvement in the planning and conduct of the study on the part of subject or partner;
• Evidence of any clinically significant medical, psychiatric, social or other condition by history, physical examination or laboratory studies that, in the opinion of the investigator, would contraindicate the administration of study medications, affect compliance, interfere with study evaluations, limit study participation, contraindicate sexual activity or confound the interpretation of study results.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

VIVUS LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John Mulhall, MD

Role: STUDY_DIRECTOR

Memorial Sloan Kettering Cancer Center

Locations

Research Site

Phoenix, Arizona, United States

Research Site

Laguna Hills, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Sacramento, California, United States

Research Site

Aurora, Colorado, United States

Research Site

Englewood, Colorado, United States

Research Site

Parker, Colorado, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Jacksonville, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Trinity, Florida, United States

Research Site

Chicago, Illinois, United States

Research Site

Chicago, Illinois, United States

Research Site

Springfield, Illinois, United States

Research Site

Indianapolis, Indiana, United States

Research Site

New Orleans, Louisiana, United States

Research Site

Shreveport, Louisiana, United States

Research Site

Baltimore, Maryland, United States

Research Site

Towson, Maryland, United States

Research Site

Brighton, Massachusetts, United States

Research Site

Burlington, Massachusetts, United States

Research Site

Jamaica Plain, Massachusetts, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

Hackensack, New Jersey, United States

Research Site

Lawrenceville, New Jersey, United States

Research Site

Brooklyn, New York, United States

Research Site

Brooklyn, New York, United States

Research Site

Garden City, New York, United States

Research Site

Great Neck, New York, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

Poughkeepsie, New York, United States

Research Site

Durham, North Carolina, United States

Research Site

Greensboro, North Carolina, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Cleveland, Ohio, United States

Research Site

Bala-Cynwyd, Pennsylvania, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Myrtle Beach, South Carolina, United States

Research Site

Rock Hill, South Carolina, United States

Research Site

Nashville, Tennessee, United States

Research Site

Arlington, Texas, United States

Research Site

Houston, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Temple, Texas, United States

Research Site

Charlottesville, Virginia, United States

Research Site

Fairfax, Virginia, United States

Research Site

Richmond, Virginia, United States

Countries

United States

References

Mulhall JP, Burnett AL, Wang R, McVary KT, Moul JW, Bowden CH, DiDonato K, Shih W, Day WW. A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. J Urol. 2013 Jun;189(6):2229-36. doi: 10.1016/j.juro.2012.11.177. Epub 2012 Dec 3.

Reference Type: DERIVED

PMID: 23219537 (View on PubMed)

Other Identifiers

TA-303

Identifier Type: -

Identifier Source: org_study_id

NCT01171001

Identifier Type: -

Identifier Source: nct_alias